Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | How disease-modifying agents may impact the role of transplantation in patients with MF

Haris Ali • 5 Oct 2022
SOHO 2022
Myelofibrosis Myeloproliferative Neoplasms Ruxolitinib

Haris Ali, MD, City of Hope, Duarte, CA, shares some insights into how disease-modifying agents may impact the role of transplantation in myelofibrosis (MF). Dr Ali first discusses the importance of clearly defining disease modification, and then goes on to explain how novel agents such as ruxolitinib have improved outcomes in patients undergoing transplantation, and future outlooks. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Haris Ali

1:29
The current role of allogeneic transplantation in MF
Haris Ali • 5 Oct 2022
1:15
The safety and efficacy of peritransplantation ruxolitinib in patients with MF
Haris Ali • 5 Oct 2022

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals